Combination with Histamine and LAK/IL-2 Therapy for the Treatment of Metastatic Melanoma / 中国肿瘤生物治疗杂志
Chinese Journal of Cancer Biotherapy
;
(6)1995.
Article
Dans Chinois
| WPRIM
| ID: wpr-683873
ABSTRACT
Objective:
To investigate the role and mechanism of histamine in regulation of C57BL/6 mice spleen derived LAK activity in vivo.Methods:
The C57BL/6 mice carrying B16 pulmonary metastatic melanoma were treated with LAK/IL 2/histamine therapy or LAK/IL 2 therapy with the aim of evaluating both anti tumor responses in vivo.Results:
It was found that the addition of histamine effectively potentiated the anti metastatic effect produced by LAK/IL 2 therapy and induced regression of NK resistant B16 pulmonary metastatic melanoma. Survival period was significantly prolonged in mice receiving LAK/IL 2/histamine as compared with LAK/IL 2 therapy alone. The effect of histamine was completely blocked by H 2 R antagonist ranitidine, and mimicked by dimaprit, a H 2 R agonist.Conclusion:
Histamine, via specific activation of H 2 R, may be an important regulator of LAK cells activity; histamine and LAK/IL 2 synergistically induce more potent antitumor efficacy in vivo .
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Cancer Biotherapy
Année:
1995
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS